Novogen makes cancer breakthrough

Novogen announced that it has successfully isolated the most potent form of CS-6.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novogen Limited (ASX: NRT) (NASDAQ: NVGN) announced yesterday that it has successfully isolated the most potent form of CS-6.

CS-6 belongs to a new class of drug candidates intended to treat most types of cancer in a complete way by targeting both the cancer and cancer stem cells. Cancer stem cells are typically resistant to the more common forms of cancer treatment, including radiotherapy and chemotherapy, and are commonly believed to be responsible for cancer reoccurrence.

CS-6 is a chiral molecule, meaning it can exist in both left and right-hand forms called enantiomers. Enantiomers often differ in their biological activity making one weaker or stronger than the other. The company has recently undertaken purification and manufacturing of pure left- and right-hand forms and has screened the compound in vitro for activity against brain cancer cells. In the report released today, analysis of this data shows that one CS-6 enantiomer is approximately 200 times more active than the other type of CS-6 against all brain cancer cell lines tested.

Novogen Chief Scientific Officer Dr Andrew Heaton said:

"the ability to manufacture CS-6 in both left- and right-hand forms represents a significant milestone in the development of this compound. The indication that one form of CS-6 is active at nanomolar concentrations against a broad spectrum of brain cancer lines is exciting and indicates that the earlier potencies we have seen against cancer cells and cancer stem cells are likely to be even greater with the purified enantiomer. We are now positioned to rapidly progress CS-6 to the clinic."

This is a major breakthrough for the company and investors have realised the importance of it by sending the share price up 54% at one stage during trading yesterday.

Foolish takeaway

In similar news, Allied Healthcare Group Limited (ASX: AHZ) has also just announced that it plans to extend the number of Australian surgeons who are actively using pre-market authorisation of CardioCel for heart conditions such as Congenital heart disease (CHD). Six days ago the company also lodged a 510(k) submission with the US Food and Drug Administration (FDA) to gain marketing approval. CHD is the leading cause of infant death globally and affects six children born in Australia every day and over 40,000 born each year in the US.

Savvy investors are now seeking growth in smaller companies. Discover two stellar small-cap opportunities now, in our brand-new research report, "2 Small Cap Superstars" — simply click here to download your FREE copy.

More reading

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. Motley Fool contributor Owen Raszkiewicz does not own shares in any of the mentioned companies.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »